– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –

Read the rest here:
Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for childhood-onset growth hormone deficiency expected to be initiated in Q1 2021

Read this article:
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

ALCESTER, United Kingdom, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology innovation company, today announces that management will be participating in three upcoming investor conferences.

Original post:
Quanta to Participate in Upcoming Virtual Investor Conferences

Granted methods patent for Versamune® platform by the United States Patent and Trademark Office Granted methods patent for Versamune® platform by the United States Patent and Trademark Office

View original post here:
PDS Biotech Announces New and Broad Versamune® Platform Patent Claims

Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus

Continue reading here:
Vaxart Hosting Key Opinion Leader Panel Call for Investors

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Event on Tuesday, December 8, 2020, from 9:00 a.m. to approximately 11:30 a.m. EST.

Link:
Syneos Health to Host Virtual Analyst and Investor Event on December 8, 2020

First patients on track for enrollment this year

Here is the original post:
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and...

? Early & High Uric Acid dose dependent association in Acute Kidney Injury from COVID-19 ? ? Early & High Uric Acid dose dependent association in Acute Kidney Injury from COVID-19 ?

See the rest here:
XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

WAKEFIELD, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that an overseas Clinical Trial Application (CTA) has been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals.

View original post here:
Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study

BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020.

See the rest here:
Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium

BRISBANE, Calif. and ST. LOUIS, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Ronald Krasnow, Esq. as Chief Operating Officer. In this newly created position, Mr. Krasnow will report to Julie Hambleton, M.D., Arch Oncology’s Interim President and Chief Executive Officer.

Read the original post:
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer

PETALUMA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., a subsidiary of Collidion, Inc. announces the development of a novel antiviral drug candidate designed to treat pulmonary infections. SPC-069 is a new class of therapy designed to treat viral, bacterial, and fungal infections in the lung and respiratory tract. This promising therapy was developed to eradicate not only common pathogens but also those caused by antibiotic resistant strains known as “Super Bugs.” The Company plans to advance this drug candidate into human clinical studies as soon as possible with a partner or upon completion of its financing.

Originally posted here:
Spectrum Antimicrobials, Inc. Announces Breakthrough Drug Candidate for Prevention and Treatment of Pulmonary Infections

WILLIAMSVILLE, N.Y., Nov. 16, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will present and meet with investors at the Virtual Fall Investor Summit. The conference is being held virtually November 16 -18, 2020.

See original here:
22nd Century Group to Present at the Virtual Fall Investor Summit on November 17

Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

Link:
TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and...

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.

Link:
Nymox Provides Update on Regulatory Filing Activities

SUNNYVALE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Simplify Medical, Inc., maker of the Simplify® Cervical Artificial Disc, announced today that David Hovda, President and Chief Executive Officer, will present at the 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum and invites investors to participate via the conference webcast. Please see additional details below:

Follow this link:
Simplify Medical to Present at the 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum

Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia

See more here:
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).

See the rest here:
Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH

– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for TransConTM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –

See the article here:
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in November.

Visit link:
CytomX Therapeutics to Present at Upcoming Investor Conferences